The vaccine development towards Toxoplasma gondii, a parasitic protozoan is an elusive goal. Our objective was to investigate the immunogenic and protective effects of a native T. gondii antigen in BALB/c mice. Balb/c mice were immunized by injecting T. gondii native antigen subcutaneously three times, one-week interval between each injection. The serum levels of anti-T. gondii IgG, IgG subclass antibodies, IFN-γ, and IL-10 were quantified using ELISA. In a challenge, immunized mice with target antigen were given a lethal dose of RH strain of T. gondii tachyzoites; the number of surviving mice was counted. The target antigen was identified in tachyzoite antigenic extract at 44-kDa molecular mass using western blotting. The 44-kDa antigen was isolated and partial characterized as protein. The immunized mice exhibited significant (p < 0.05) elevated levels of specific anti-T. gondii IgG, IgG1 and IgG2a antibodies compared to control groups. Furthermore, the 44-kDa antigen significantly (p < 0.001) stimulates the synthesis of IFN-γ, as well as IL-10 indicating the native antigen might elicit immune responses of both Th1 and Th2 types. Furthermore, immunized BALB/c mice displayed prolonged survival time up to 12 days against lethal challenge with T. gondii RH strain in comparison with non-immunized controls. In conclusion, immunization of BALB/c mice with 44-kDa native antigen generates immunoprotective responses against T. gondii infection and increases survival time. The 44-kDa antigen may have the potential as a promising candidate vaccine against T. gondii infection and further investigations based on recombinant target protein will be performed.
No takes yet. Share an insight, caveat, or question.
Soudi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: